Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Webinar: InMed Pharmaceuticals

Webinar: InMed Pharmaceuticals

InMed Pharmaceuticals — 14 videos in collection

More on this equity

InMed Pharmaceuticals (INM) is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol, and is developing IntegraSyn to produce pharmaceutical-grade cannabinoids. InMed recently announced that it has entered into a definitive agreement to acquire BayMedica, a revenue-stage biotechnology company leveraging synthetic biology and pharmaceutical chemistry to develop an efficient, scalable and proprietary platform to produce high-quality, rare cannabinoids for consumer applications. The combined company will be a market leader in the manufacture of rare cannabinoids.

In this webinar, InMed chief executive officer Eric Adams and BayMedica chief executive officer Dr Shane Johnson discuss the acquisition and their plans for the newly combined company.

< Previous
Next >

You may also be interested in these:

Healthcare

InMed Pharmaceuticals: Edison Open House Healthcare 2022

Healthcare

InMed Pharmaceuticals – Introducing the BayMedica team

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free